ArticleSSM - population health2023
Global, regional, and national trends in mesothelioma burden from 1990 to 2019 and the predictions for the next two decades.
Article in SSM - population health, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Asbestos mineral fibre exposure significantly affects volatile organic compound profiles of mesothelial cell lines in vitro.Scientific reports · 2026Article
- Persistence burden and poor survival of pleural mesothelioma in central Italy, 2013-2022: a population-based study thirty years after asbestos ban.BMC public health · 2026Article
- Pulmonary Arterial Hypertension and Cancer: Unveiling Parallels in Epidemiology, Clinical Pathways, and Therapeutic Strategies.Journal of market access & health policy · 2026Article
- Inactivation ofLife (Basel, Switzerland) · 2026Article
- Trends of asthma mortality in china: a comprehensive analysis by population, region, and sex with future projections.BMC pulmonary medicine · 2025Article
- Pleural mesothelioma.Nature reviews. Disease primers · 2025Review
- Health inequality and the global burden of mesothelioma: insights from the global burden of disease study 2021.BMC cancer · 2025Article
- Global mortality burden of lung cancer and mesothelioma attributable to occupational asbestos exposure and the impact of national asbestos ban policies: a population-based study, 1990-2021.BMJ public health · 2025Article
- Immunotherapy for Treatment of Pleural Mesothelioma: Current and Emerging Therapeutic Strategies.International journal of molecular sciences · 2024Review
- Immunotherapy for advanced and recurrent malignant pleural mesothelioma.The Cochrane database of systematic reviews · 2024Article
- Asbestos ban policies and mesothelioma mortality in Greece.BMC public health · 2024Article
- Telomere length andRadiology and oncology · 2024Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: We aimed to analyze the secular trends in mesothelioma burden, the effect of age, period, and birth cohort, and project the global burden over time. Material and methods: Based on the mesothelioma incidence, mortality, and Disability-Adjusted Life Years (DALYs) data from 1990 to 2019 in Global Burden of Diseases (GBD) database, the annual percentage change (APC) and average annual percent change (AAPC), calculated from joinpoint regression model, was used to describe the burden trends. An age-period-cohort model was utilized to disentangle age, period, and birth cohort effects on mesothelioma incidence and mortality trends. The mesothelioma burden was projected by the Bayesian age-period-cohort (BAPC) model. Results: Globally, there were the significant declines in age-standardized incidence rate (ASIR) (AAPC = -0.4, 95%CI: -0.6,-0.3, Conclusions: The global burden of mesothelioma declined over the past 30 years, with variability across regions and countries/territories, and this trend will continue in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.